Generic Name and Formulations:
Glatiramer acetate 20mg/mL, 40mg/mL; soln for SC inj; contains mannitol; preservative-free.
Indications for COPAXONE:
Relapsing forms of multiple sclerosis.
Supervise 1st dose. Give only by SC inj into arms, abdomen, hips, thighs. Rotate inj sites. ≥18yrs: 20mg once daily or 40mg three times weekly (at least 48hrs apart). The 20mg/mL and 40mg/mL injections are not interchangeable.
<18yrs: not established.
Risk of post-injection reactions. May potentially interfere with immune functions. Pregnancy (Cat.B). Nursing mothers.
Inj site reactions, vasodilatation, rash, dyspnea, chest pain, asthenia, infection, pain, nausea, anxiety; rare: lipoatrophy, skin necrosis.
Single-use prefilled syringes 20mg/mL—30; 40mg/mL—12
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma